Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...

US FDA approves Keytruda and Keytruda Qlex, each with Trodelvy as first-line treatment of PD-L1+ (CPS =10) advanced TNBC: Rahway, New Jersey Friday, June 26, 2026, 09:00 Hrs [IST] ...

Merck MRK announced that the European Commission has approved its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), and ...

The approvals are based on data from the pivotal Phase III LITESPARK-022 trial, which enrolled 1,841 patients.

The approval is based on results from the KEYNOTE-905/EV-303 trial, conducted in partnership with Pfizer and Astellas.

Trodelvy dosing is 10 mg/kg IV on days 1 and 8 of 21-day cycles, continued until progression or unacceptable toxicity; pembrolizumab schedules follow prescriber determination. Safety requires ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv ...

Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

Keytruda, an immunotherapy agent, demonstrated significant improvement in both distant metastasis-free survival and recurrence-free survival compared to placebo. Keytruda (pembrolizumab) in the ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-010 trial investigating KEYTRUDA, ...

Keytruda offered event-free survival advantages across different patient subgroups when used for the adjuvant treatment of early lung cancer, according to data presented at ASCO 2022. (Merck & Co.) As ...